DUBLIN, Dec. 4, 2019 /PRNewswire/ -- The "Global Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Region/Country Data and Competitive Landscape - Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

The market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2025.

Growth in this market is driven by the rising incidence of hematologic malignancies, increasing adoption of inorganic growth strategies in the market, favorable reimbursement scenario in the global hematologic malignancies testing market, and increasing funding in hematologic malignancies testing market. The massive scope in the emerging economies and technological advancements in the field of molecular diagnostics are also expected to provide growth opportunities for players in the market.

The molecular discovery of disease-causing genes in blood cancers has led to the global phenomenon known as precision diagnostics in hematologic malignancies. By understanding the underlying molecular mechanisms of diseases and genetic composition and regulation in humans, molecular diagnostics have empowered physicians to move away from broadly classifying patients according to diseases, shifting toward individualized treatment, with the adoption of specialized kits, and services aimed at an early screening of disease.

The global hematologic malignancies testing market has witnessed significant growth, attributing to the increasing demand for multiple biomarker based-molecular diagnostics. The developments have been instrumental in improving the quality of life and reducing the cost and time of treatment, boosting the growth of the overall healthcare diagnostics market. Further, the increasing awareness and adoption of the precision diagnostic approach in developed as well as developing countries is the key driver for the growth of the global hematologic malignancies testing market.

The evolution of new technologies is enabling the acquisition of more information for more exhaustive characterization of the disease state, the most suitable treatment alternatives for a patient, or in the case of blood cancer, the rapid identification of a specific gene that could be responsible for a particular carcinoma.

Approaches that have the potential to address this requirement for highly increasing amounts of data include multi-marker or multiplexed approaches (methods that can test for multiple biomarkers in a single assay) and gene sequencing that enable the detection of multiple defects that are associated with a particular subset of patients with a disease. The practical application of these methods can be challenging owing to the complexity of the involved assays.

Key Questions Answered in this Report:

Key Topics Covered:

Executive Summary

1 Market Overview1.1 Introduction1.2 Historical Perspective1.3 Types of Hematologic Malignancy Diagnostic Tests1.4 Global Footprint1.5 Trends and Future Potential

2 Market Dynamics2.1 Market Drivers2.1.1 Rising Incidence of Hematologic Malignancies2.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market2.1.3 Favorable Reimbursement Scenario in the Global Hematologic Malignancies Testing Market2.1.4 Increase in Funding in Hematologic Malignancies Testing Market2.2 Restraints2.2.1 High Pricing Pressure2.2.2 Lack of Trained Professionals2.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers2.3 Market Opportunities2.3.1 Opportunities in the Emerging Economies2.3.2 Technological Advancements in the Field of Molecular Diagnostics

3 Competitive Landscape3.1 Key Strategies and Developments3.2 Product Scenario3.3 Funding Scenario3.4 Market Share Analysis3.5 Growth Share Analysis (Opportunity Mapping)3.6 Comprehensive Competitive Index

4 Industry Insights4.1 Regulatory Framework4.1.1 Legal Requirements and Framework in the U.S.4.1.2 Legal Requirements and Framework in Europe4.1.3 Legal Requirements and Framework in Asia-Pacific4.1.3.1 Japan4.1.3.2 China4.2 Reimbursement Scenario4.3 Physicians' Perceptions

5 Global Hematologic Malignancies Testing Market (by Product)5.1 Services5.2 Kits5.2.1 Gene Panels5.2.2 Molecular Clonality Testing5.2.3 Translocation Testing5.2.4 Mutation Testing5.2.5 Minimal Residual Disease (MRD) Testing

6 Global Hematologic Malignancies Testing Market (by Disease)6.1 Leukemia6.2 Lymphoma6.3 Multiple Myeloma6.4 Myeloproliferative Neoplasms6.5 Myelodysplastic Syndromes

7 Global Hematologic Malignancies Testing Market (by Technology)7.1 Next-Generation Sequencing (NGS)7.2 Polymerase Chain Reaction (PCR)7.3 Fluorescence in Situ Hybridization (FISH)7.4 Immunohistochemistry (IHC)7.5 Flow Cytometry7.6 Other Technologies

8 Global Hematologic Malignancies Testing Market (by End User)8.1 Specialty Clinics and Hospitals8.2 Diagnostic Laboratories8.3 Reference Laboratories8.4 Research Institutions

9 Global Hematologic Malignancies Testing Market (by Region)

10 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/r9y3z8

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-hematologic-malignancies-testing-market-2019-2025-increasing-adoption-of-inorganic-growth-strategies-in-the-market-300969229.html

SOURCE Research and Markets

Read the original here:
Global Hematologic Malignancies Testing Market 2019-2025: Increasing Adoption of Inorganic Growth Strategies in the Market - P&T Community

Comments are closed.